Literature DB >> 25339046

Colorectal cancer incidence and mortality in China, 2010.

Zhao-Xu Zheng1, Rong-Shou Zheng, Si-Wei Zhang, Wan-Qing Chen.   

Abstract

BACKGROUND: The National Central Cancer Registry of China (NCCR) affiliated to the Bureau of Disease Control, National Health and Family Planning Commission of China is responsible for cancer surveillance in the entire country. Cancer registration data from each local registry located in each province are collected by NCCR annually to be analyzed and published to provide useful information for policy makers and cancer researchers.
MATERIALS AND METHODS: Until 1st June, 2013, 219 population-based cancer registries submitted data of 2010 to the National Central Cancer Registry of China covering about 207,229,403 population, and 145 cancer registries were selected after quality evaluation for this study. Colorectal cancer cases were selected from the database according to ICD-10 coded as "C18-C20". We calculated the crude incidence and mortality rates by sex, age groups and location (urban/rural). The China population in 2000 and Segi's population were used as standardized populations for the calculation of age-standardized rates. The 6th National Population Census data of China was used to combined with the cancer registries' data to estimate the colorectal cancer burden in China in 2010.
RESULTS: Colorectal cancer was the sixth most common cancer in China. It was estimated that there were 274,841 new cases diagnosed in 2010 (157,355 in males and 117,486 in females), with the crude incidence rate of 20.1/100,000, highest in males in urban areas. Age-standardized rates by China standard population of 2000 (ASRcn) and World standard population (Segi's population, ASRwld) for incidence were 16.1/100,000 and 15.9/100,000 respectively. There were 132,110 cases estimated to have died from colorectal cancer in China in 2010 (76,646 men and 55,464 women) with the crude mortality rate of 10.1/100,000. The ASRcn and ASRwld for mortality were 7.55/100,000 and 7.44/100,000 respectively, higher in males and urban areas than in females and rural areas. The incidence and mortality rates increased with age, reaching peaksin the 80-84 year old, and oldest age groups, respectively.
CONCLUSIONS: Colorectal cancer is one of the most common incident cancers and cause of cancer death in China. Primary and secondary prevention, with attention to a health lifestyle, physical activity and screening should be enhanced in the general population.

Entities:  

Mesh:

Year:  2014        PMID: 25339046     DOI: 10.7314/apjcp.2014.15.19.8455

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  34 in total

1.  Significant association of EED promoter hypomethylation with colorectal cancer.

Authors:  Xiuru Ying; Ranran Pan; Jie Zhong; Boyi Wu; Yuting Jiang; Jieer Ying; Cong Zhou; Jie Dai; Shuangying Zhao; Yinan Shen; Wei Zhang; Shiwei Duan
Journal:  Oncol Lett       Date:  2019-06-04       Impact factor: 2.967

2.  Decreased expression of dual specificity phosphatase 22 in colorectal cancer and its potential prognostic relevance for stage IV CRC patients.

Authors:  Dan Yu; Zhenli Li; Meifu Gan; Hanyun Zhang; Xiaoyang Yin; Shunli Tang; Ledong Wan; Yiping Tian; Shuai Zhang; Yimin Zhu; Maode Lai; Dandan Zhang
Journal:  Tumour Biol       Date:  2015-06-02

3.  Metabolomics approach for predicting response to neoadjuvant chemotherapy for colorectal cancer.

Authors:  Kai Yang; Fan Zhang; Peng Han; Zhuo-Zhong Wang; Kui Deng; Yuan-Yuan Zhang; Wei-Wei Zhao; Wei Song; Yu-Qing Cai; Kang Li; Bin-Bin Cui; Zheng-Jiang Zhu
Journal:  Metabolomics       Date:  2018-08-16       Impact factor: 4.290

4.  Long non-coding RNA LINC01296 is a potential prognostic biomarker in patients with colorectal cancer.

Authors:  Jia-Jun Qiu; Jing-Bin Yan
Journal:  Tumour Biol       Date:  2015-04-17

5.  CHST7 Gene Methylation and Sex-Specific Effects on Colorectal Cancer Risk.

Authors:  Haoran Bi; Yupeng Liu; Rui Pu; Tingting Xia; Hongru Sun; Hao Huang; Lei Zhang; Yuanyuan Zhang; Ying Liu; Jing Xu; Jiesheng Rong; Yashuang Zhao
Journal:  Dig Dis Sci       Date:  2019-02-28       Impact factor: 3.199

6.  A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer.

Authors:  Ranhua Cao; Shuai Zhang; Dedong Ma; Likuan Hu
Journal:  Med Oncol       Date:  2014-12-07       Impact factor: 3.064

7.  Metabolic phenotyping to monitor chronic enteritis canceration.

Authors:  Fan Zhang; Chunbo Li; Kui Deng; Zhuozhong Wang; Weiwei Zhao; Kai Yang; Chunyan Yang; Zhiwei Rong; Lei Cao; Yaxin Lu; Yue Huang; Peng Han; Kang Li
Journal:  Metabolomics       Date:  2020-02-24       Impact factor: 4.290

8.  Combined identification of long non-coding RNA CCAT1 and HOTAIR in serum as an effective screening for colorectal carcinoma.

Authors:  Weimin Zhao; Mu Song; Jie Zhang; Mulati Kuerban; Haijiang Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 9.  Advances and Insights of APC-Asef Inhibitors for Metastatic Colorectal Cancer Therapy.

Authors:  Xiuyan Yang; Jie Zhong; Qiufen Zhang; Li Feng; Zhen Zheng; Jian Zhang; Shaoyong Lu
Journal:  Front Mol Biosci       Date:  2021-04-22

10.  Incidence trends and age distribution of colorectal cancer by subsite in Guangzhou, 2000-2011.

Authors:  Qin Zhou; Ke Li; Guo-Zhen Lin; Ji-Chuan Shen; Hang Dong; Yu-Ting Gu; Hua-Zhang Liu
Journal:  Chin J Cancer       Date:  2015-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.